{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:23:38Z","timestamp":1761823418250},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2011,4,28]],"date-time":"2011-04-28T00:00:00Z","timestamp":1303948800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1007\/s12282-011-0270-9","type":"journal-article","created":{"date-parts":[[2011,4,27]],"date-time":"2011-04-27T09:07:25Z","timestamp":1303895245000},"page":"253-258","source":"Crossref","is-referenced-by-count":13,"title":["Safety of adjuvant trastuzumab for HER-2-overexpressing elderly breast cancer patients: a multicenter cohort study"],"prefix":"10.1007","volume":"19","author":[{"given":"Masataka","family":"Sawaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Mukai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nahomi","family":"Tokudome","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naruto","family":"Taira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiro","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiyo","family":"Horio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukari","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuo","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,4,28]]},"reference":[{"key":"270_CR1","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene. Science. 1987;235:177\u201382.","journal-title":"Science"},{"key":"270_CR2","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1126\/science.2470152","volume":"244","author":"DJ Slamon","year":"1989","unstructured":"Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707\u201312.","journal-title":"Science"},{"key":"270_CR3","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1200\/JCO.1992.10.7.1049","volume":"10","author":"BA Gusterson","year":"1992","unstructured":"Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Save-Soderborgh J, Anbazhagan R, et al. Prognostic importance of c-erbb-2 expression in breast cancer. International (Ludwig) breast cancer study group. J Clin Oncol. 1992;10:1049\u201356.","journal-title":"J Clin Oncol"},{"key":"270_CR4","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1200\/JCO.1993.11.10.1936","volume":"11","author":"R Seshadri","year":"1993","unstructured":"Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V, Kitchen P. Clinical significance of HER-2\/neu oncogene amplification in primary breast cancer. The South Australian breast cancer study group. J Clin Oncol. 1993;11:1936\u201342.","journal-title":"J Clin Oncol"},{"key":"270_CR5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0378-1119(94)00866-Q","volume":"159","author":"PM Ravdin","year":"1995","unstructured":"Ravdin PM, Chamness GC. The c-erbb-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers\u2014a review. Gene. 1995;159:19\u201327.","journal-title":"Gene"},{"key":"270_CR6","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1200\/JCO.1997.15.8.2894","volume":"15","author":"MF Press","year":"1997","unstructured":"Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou JY, Ma Y, et al. HER-2\/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol. 1997;15:2894\u2013904.","journal-title":"J Clin Oncol"},{"key":"270_CR7","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","volume":"353","author":"EH Romond","year":"2005","unstructured":"Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673\u201384.","journal-title":"N Engl J Med"},{"key":"270_CR8","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","volume":"353","author":"MJ Piccart-Gebhart","year":"2005","unstructured":"Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659\u201372.","journal-title":"N Engl J Med"},{"key":"270_CR9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(07)60028-2","volume":"369","author":"I Smith","year":"2007","unstructured":"Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 2007;369:29\u201336.","journal-title":"Lancet"},{"key":"270_CR10","first-page":"500S","volume":"69","author":"D Slamon","year":"2009","unstructured":"Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Rolski J, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC \u2192\u00a0T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC \u00a0\u2192\u00a0TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2neu positive early breast cancer patients: Bcirg 006 study. Cancer Res. 2009;69:500S.","journal-title":"Cancer Res"},{"issue":"Suppl 2","key":"270_CR11","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000055403","volume":"61","author":"N Cook-Bruns","year":"2001","unstructured":"Cook-Bruns N. Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer. Oncology. 2001;61(Suppl 2):58\u201366.","journal-title":"Oncology"},{"key":"270_CR12","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.breast.2003.09.002","volume":"13","author":"TM Suter","year":"2004","unstructured":"Suter TM, Cook-Bruns N, Barton C. Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer. Breast. 2004;13:173\u201383.","journal-title":"Breast"},{"key":"270_CR13","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.1200\/JCO.2006.09.1611","volume":"25","author":"TM Suter","year":"2007","unstructured":"Suter TM, Procter M, van Veldhuisen DJ, Muscholl M, Bergh J, Carlomagno C, et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol. 2007;25:3859\u201365.","journal-title":"J Clin Oncol"},{"key":"270_CR14","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s10147-009-0898-z","volume":"14","author":"M Ishihara","year":"2009","unstructured":"Ishihara M, Mukai H, Nagai S, Mukohara T. Cardiac safety of trastuzumab as adjuvant treatment for Japanese patients with early breast cancer. Int J Clin Oncol. 2009;14:431\u20135.","journal-title":"Int J Clin Oncol"},{"key":"270_CR15","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1093\/annonc\/mdq096","volume":"21","author":"RB Costa","year":"2010","unstructured":"Costa RB, Kurra G, Greenberg L, Geyer CE. Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer. Ann Oncol. 2010;21:2153\u201360.","journal-title":"Ann Oncol"},{"key":"270_CR16","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.1200\/JCO.2009.26.0463","volume":"28","author":"M Procter","year":"2010","unstructured":"Procter M, Suter TM, de Azambuja E, Dafni U, van Dooren V, Muehlbauer S, et al. Longer-term assessment of trastuzumab-related cardiac adverse events in the herceptin adjuvant (HERA) trial. J Clin Oncol. 2010;28:3422\u20138.","journal-title":"J Clin Oncol"},{"key":"270_CR17","doi-asserted-by":"crossref","first-page":"3808","DOI":"10.1200\/JCO.2006.10.4976","volume":"25","author":"MC Pinder","year":"2007","unstructured":"Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol. 2007;25:3808\u201315.","journal-title":"J Clin Oncol"},{"key":"270_CR18","doi-asserted-by":"crossref","first-page":"5296","DOI":"10.1002\/cncr.24621","volume":"115","author":"XL Du","year":"2009","unstructured":"Du XL, Xia R, Liu CC, Cormier JN, Xing Y, Hardy D, et al. Cardiac toxicity associated with anthracycline-containing chemotherapy in older women with breast cancer. Cancer. 2009;115:5296\u2013308.","journal-title":"Cancer"},{"key":"270_CR19","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1200\/JCO.2009.27.3615","volume":"28","author":"D Cardinale","year":"2010","unstructured":"Cardinale D, Colombo A, Torrisi R, Sandri MT, Civelli M, Salvatici M, et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin i evaluation. J Clin Oncol. 2010;28:3910\u20136.","journal-title":"J Clin Oncol"},{"key":"270_CR20","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1200\/JCO.2007.13.5467","volume":"26","author":"EA Perez","year":"2008","unstructured":"Perez EA, Suman VJ, Davidson NE, Sledge GW, Kaufman PA, Hudis CA, et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the north central cancer treatment group N9831 adjuvant breast cancer trial. J Clin Oncol. 2008;26:1231\u20138.","journal-title":"J Clin Oncol"},{"key":"270_CR21","doi-asserted-by":"crossref","unstructured":"Rastogi P, Jeong J, Geyer CE, Costantino JP, Romond EH, Ewer MS, et al. Five year update of cardiac dysfunction on nsabp B-31, a randomized trial of sequential doxorubicin\/cyclophosphamide (AC)\u00a0\u2192\u00a0paclitaxel (T) vs. AC\u00a0\u2192\u00a0T with trastuzumab(H). J Clin Oncol. 2007;25:suppl;abstr LBA513.","DOI":"10.1200\/jco.2007.25.18_suppl.lba513"},{"key":"270_CR22","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1200\/JCO.2009.26.0125","volume":"28","author":"PG Morris","year":"2010","unstructured":"Morris PG, Hudis CA. Trastuzumab-related cardiotoxicity following anthracycline-based adjuvant chemotherapy: how worried should we be? J Clin Oncol. 2010;28:3407\u201310.","journal-title":"J Clin Oncol"},{"key":"270_CR23","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1200\/JCO.2007.11.0106","volume":"25","author":"ML Telli","year":"2007","unstructured":"Telli ML, Hunt SA, Carlson RW, Guardino AE. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol. 2007;25:3525\u201333.","journal-title":"J Clin Oncol"},{"key":"270_CR24","doi-asserted-by":"crossref","first-page":"7820","DOI":"10.1200\/JCO.2005.13.300","volume":"23","author":"MS Ewer","year":"2005","unstructured":"Ewer MS. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol. 2005;23:7820\u20136.","journal-title":"J Clin Oncol"},{"key":"270_CR25","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1200\/JCO.2005.04.9551","volume":"24","author":"V Guarneri","year":"2006","unstructured":"Guarneri V, Lenihan DJ, Valero V, Durand JB, Broglio K, Hess KR, et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the MD Anderson cancer center experience. J Clin Oncol. 2006;24:4107\u201315.","journal-title":"J Clin Oncol"},{"key":"270_CR26","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1200\/JCO.2006.09.2775","volume":"25","author":"AC Wolff","year":"2007","unstructured":"Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118\u201345.","journal-title":"J Clin Oncol"},{"key":"270_CR27","doi-asserted-by":"crossref","unstructured":"Sawaki M, Tokudome N, Mizuno T, Nakayama T, Taira N, Bando H, et al. Evaluation of trastuzumab without chemotherapy as a postoperative adjuvant therapy in HER2 positive elderly breast cancer patients: N-SAS BC 07 (RESPECT study). Jpn J Clin Oncol. doi: 10.1093\/jjco\/HYR011 .","DOI":"10.1093\/jjco\/hyr011"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-011-0270-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12282-011-0270-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-011-0270-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T17:13:47Z","timestamp":1592500427000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12282-011-0270-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,28]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["270"],"URL":"https:\/\/doi.org\/10.1007\/s12282-011-0270-9","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,28]]}}}